Management Strategies for Cardiogenic Shock

(VANQUISH SHOCK Trial)

Recruiting at 3 trial locations

Overseen By John Kirk

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: STAVROS G DRAKOS

Disqualifiers: Septic, Hemorrhagic, Anaphylactic, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

500 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to better understand how to manage and treat cardiogenic shock, a serious condition where the heart suddenly can't pump enough blood to meet the body's needs. Researchers are collecting data from patients at four major centers to learn about the treatment and outcomes of this condition. The trial is open to individuals diagnosed with cardiogenic shock, including those with complications from heart attacks or severe heart failure. However, patients with shock from non-heart-related causes, such as infections or allergies, are not eligible. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to enhance the quality and outcomes in managing cardiogenic shock through a collaborative, multi-center approach. Unlike traditional methods that focus on singular treatment protocols, this initiative seeks to integrate diverse strategies and expertise from multiple centers to improve patient outcomes. The trial's innovative approach could lead to the development of best practices that are more effective and efficient, potentially setting new standards for treating cardiogenic shock across various healthcare settings.

Who Is on the Research Team?

Stavros Drakos, M.D.

Principal Investigator

University of Utah

Are You a Good Fit for This Trial?

Inclusion Criteria

Primary diagnosis of cardiogenic shock at time of index evaluation; including acute myocardial infarction- and acute decompensated heart failure-cardiogenic shock phenotypes

Patients with cardiac arrest complicating cardiogenic shock and those with massive pulmonary embolism with right ventricular cardiogenic shock will also be eligible for the registry

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Hospital Admission and Initial Management

Participants are admitted to the hospital and undergo initial management for cardiogenic shock, including baseline assessments and potential initiation of mechanical circulatory support.

Duration varies based on patient condition

In-hospital stay

Follow-up

Participants are monitored for safety and effectiveness after discharge, with evaluations at 30 days, 6 months, and 1 year.

1 year

3 follow-up visits (30 days, 6 months, 1 year)

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

STAVROS G DRAKOS

Lead Sponsor

Trials

3

Recruited

600+